Dolutegravir / lamivudine for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults and adolescents over 12 years of age

Document first published:
Page updated:
Topic:
Publication type:

Dolutegravir/lamivudine for the treatment of HIV infected adults and adolescents >12 years of age is recommended to be available as a treatment option through routine commissioning within the criteria set out in this document.

Document

Dolutegravir / lamivudine for the treatment of HIV infected adults and adolescents over 12 years of age

Dolutegravir / lamivudine for the treatment of HIV infected adults and adolescents over 12 years of age

  • PDF
  • 131 KB
  • 13 pages

Document

Stakeholder Engagement Report

Stakeholder Engagement Report

  • PDF
  • 80 KB
  • 3 pages

Document

Clinical Panel Report

Clinical Panel Report

  • PDF
  • 80 KB
  • 2 pages

Document

CPAG Summary Report

CPAG Summary Report

  • PDF
  • 90 KB
  • 8 pages